Business Wire

VA-REGULA

Share
Regula Survey Reveals 80% of Decision Makers Link Digital Nomad Movement to Increased Identity Fraud

According to the survey’s results, the number of foreign document verification cases in all parts of the world has grown by an average of 21% since the summer of 2021. It’s even higher in the US and UAE: these countries are experiencing a 25% increase. As for industries, Insurance appears to be dealing with the majority of foreign IDs (+27% compared to summer 2021), followed by Financial and Banking Services (+25%).

The rise in foreign clients has led to a spike in identity fraud. Identity verification (IDV) of digital nomads can be a tricky task for many businesses as their established processes are not designed for such a large variety of foreign IDs, and thus require revamping. This difficulty potentially results in an elevated risk of organizations facing more identity fraud. Indeed, Regula’s survey confirms these sentiments among business decision makers, with 40% of them highlighting the increase in fraud as a primary challenge when it comes to identity verification for digital nomads. The UAE and Mexico are even more agitated, as 51% and 49% of decision makers in those countries feel the risk of falling victim to fraud.

Furthermore, 80% of decision makers participating in Regula’s survey directly associate the digital nomad movement with identity fraud, saying that it is increasing the number of forged or counterfeited documents organizations find during verification. The average growth in identity document fraud is stated to be 14%; however, in the Insurance industry it is 22%, and in the Financial and Banking Services it is nearly 19%.

New solution. This situation is forcing businesses to introduce new methods and technologies for identity verification. As the survey shows, 57% of organizations have implemented biometric authentication to detect and prevent fraud during the digital onboarding process. To combat document forgery, 53% of respondents say they have decided to verify only electronic documents—i.e., ones that contain an RFID chip, a reliable security feature that makes counterfeiting almost impossible. The most vulnerable industries, Financial Services and Insurance, are even more inclined to switch to this option: 61% of decision makers from these sectors confirmed they are already accepting only e-docs.

The option to grant access to products and services only to digital nomads who have electronic documents seems to be an effective measure. It can help organizations cope with the growing number of various IDs by limiting their possible variety. It also facilitates document verification, since e-docs are currently considered to be the most secure. However, to be able to combat document fraud, it’s not enough to rely only on document security features. While it’s nearly impossible for fraudsters to counterfeit a microchip in an electronic passport, they can still manipulate its data or intercept verification results on a smartphone. That is why organizations need a “zero-trust-to-mobile” approach and a reliable NFC verification technology to confirm the authenticity of both the chip and its data. A good example is Regula Document Reader SDK: it enables complete server-side verification of e-documents to ensure the chip's authenticity and data integrity.

“Identity fraud is flourishing, and overall digitalization, along with mass people movement and relocation are creating new pitfalls for businesses, which are trying to keep pace. In this changing world, organizations inevitably need to start adopting new technologies to enable robust and reliable verification, especially for remote processes. They will also be interested in the possibilities to scale and adapt their IDV processes to new scenarios and requirements. Leading vendors like Regula are responding to this shift as well, by introducing new technologies and capabilities for any use case in any industry,” says Henry Patishman, Executive Vice President, Identity Verification Solutions at Regula.

To learn more about the identity fraud associated with the digital nomad movement, read the full report.

*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.

About Regula

With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240115684173/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release

The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl

Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release

Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds

WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release

EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye